idecabtagene vicleucel Abecma
Selected indexed studies
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. (N Engl J Med, 2021) [PMID:33626253]
- ** (, 2022) [PMID:37797149]
- Idecabtagene vicleucel (Abecma) for multiple myeloma. (Med Lett Drugs Ther, 2022) [PMID:36384767]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Impact of Manufacturing Procedures on CAR T Cell Functionality. (2022) pubmed
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. (2021) pubmed
- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. (2023) pubmed
- Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. (2024) pubmed
- Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. (2025) pubmed
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. (2023) pubmed
- Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. (2025) pubmed
- PMID:37797149 (2022) pubmed
- Idecabtagene vicleucel (Abecma) for multiple myeloma. (2022) pubmed
- Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) pubmed